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Background: Non-febrile illness seizures may present in previously healthy children
as afebrile seizures associated with minor infections, such as mild gastroenteritis or
respiratory tract infections, and are linked to a genetic predisposition. For the novel
human coronavirus SARS-CoV-2, causing COVID-19, fever, cough, and gastrointestinal
complaints are the most common symptoms in children, and a hyperimmune response
may be present. No detailed temporally associated neurological complications have been
documented in pediatric case series so far.
Case description:We present the case of a 3-months-old girl with non-febrile repeated
seizures in a COVID-19 family setting. The infant started with a mild fever and cough
that lasted for 2 days. At day 6 from onset, the girl presented with two focal motor
seizures with impaired consciousness and awareness. All investigations ruled out signs
of meningo-encephalitis or active epilepsy, including normal electroencephalogram and
cerebral magnetic resonance imaging. PCR from nasal and throat swabs was positive
for SARS-CoV-2. Remarkably, blood ferritin and D-dimer levels were increased. At day 9,
the infant presented another afebrile motor seizure, and levetiracetam dose was modified
there was a favorable response within 3 months of the follow-up. Much interest has been
raised with regards to host genetic determinants to disease severity and susceptibility
to COVID-19. We thus performed whole exome sequencing, revealing a pathogenic
frameshift mutation in the PRRT2 gene in both the mother and the infant. The mother
had presented two late infantile febrile convulsions with normal outcome afterwards.
Discussion: The hyperimmune response described in adult cases with COVID-19 can
be seen in infants, even in the absence of respiratory symptoms. Moreover, COVID-19
may present in infants as non-febrile seizures, triggering early onset seizures in infants
with a genetic predisposition. In this pandemic situation, precision medicine using
García-Howard et al. Benign Infantile Seizures and COVID-19
massive sequencing can shed light on underlying molecular mechanisms driving the host
response to COVID-19.
Keywords: coronavirus, SARS-CoV-2, COVID-19, pediatric COVID-19, non-febrile seizures, afebrile seizures,
PRRT2 mutations, benign familial infantile epilepsy
INTRODUCTION
Non-febrile illness seizures are described as afebrile seizures
associated with minor infections in previously healthy children.
Seizures occur mainly in infants in the setting of acute
infections, such as mild gastroenteritis or respiratory tract
infections, without structural correlate or hydro-electrolytic
imbalance (1–4). Rotaviruses are frequently found in non-febrile
convulsions associated with gastroenteritis, and noroviruses
have been recently identified as an emergent pathogen in
these cases (1, 5). In infants with non-febrile seizures related
to respiratory tract infections, common seasonal viruses,
such as influenza, respiratory syncytial virus (RSV), and
metapneumovirus, have been pointed out as plausible causative
pathogens (3, 4, 6).
Human coronavirus (HCoV) causes respiratory infections
with a seasonal pattern in children, and in some cases,
extra-pulmonar manifestations have been described.
It has been increasingly recognized that HCoV shows
some neurotropism due to its capacity to reach the
central nervous system after the nasal infection, shown
for HCoV-OC43 and HCoV-NL63 (7, 8). Neurological
complications of common HCoV infections have been
reported, including febrile seizures, convulsions, loss of
consciousness, encephalomyelitis, and encephalitis (9).
Another HCoV, SARS-CoV, emerged in Guandong province,
southern China, in 2002, and it spread to many countries
and caused severe lower respiratory tract infection with
an overall case-fatality rate of 10%. The SARS-CoV was
associated with milder disease in children compared to
adults, with some case series reporting febrile seizures in
10% of a total sample of 41 children (10–12). Fortunately, no
human SARS-CoV infections have been identified since July
2003 (8).
In December 2019, a novel HCoV (SARS-CoV-2) was
reported from Wuhan city, Hubei province, China, and it
rapidly spread worldwide causing a pandemic outbreak by
March 2020, producing a respiratory disease called COVID-
19. Initial case series have shown that children present milder
clinical symptoms than adults and that most pediatric cases
were infected in family clusters. Fever, cough, respiratory
distress, myalgia, and gastrointestinal complaints are the most
common symptoms (13–18), but no detailed neurological
complications have been documented in pediatric case series
so far.
In this article, we describe the case of a 3-months-old
girl with non-febrile repeated seizures in a COVID-19 family
setting. Whole exome sequencing was applied and revealed
an underlying genetic pathogenic variant that may cause the
clinical presentation.
CASE PRESENTATION
A previously healthy, with uneventful pregnancy and
delivery, 3-months-old girl was admitted to the pediatric
emergency department early morning on April 1 after her
mother reported two episodes of convulsions without fever.
During the night, the mother, who was a nurse, reported
a first episode of clonic movements of the face with tonic
posture of extremities and trismus, without consciousness,
lasting 3min approximately. Few hours later, the infant
presented with a second episode, described as staring gaze,
clonic movements of the face and right extremities, and
repeating sucking movements of the mouth, lasting <5min.
At admission, vital constants were normal; physical and
neurological examination showed mild hypotonia and
drowsiness without focal deficits. The mother informed us
that, on March 27–28, the infant had presented with a low fever
of <38.1◦C, rhinorrhea, cough, and diarrhea with subsequent
improvement. No fever was documented the 3 days before
these convulsions. Interestingly, the mother referred herself
as having persistent symptoms of anosmia and dysgeusia
since March 23, and showed no signs of fever or respiratory
symptoms since.
At admission, patient blood tests did not show any
abnormalities except for a high ferritin value (385 µg/L;
normal values 10–204). PCRs of nasopharyngeal and throat
swabs tested positive for SARS-CoV-2. Additional testing for
other viruses was negative, including HCoV-NL63, HCoV-OC43,
HCoV-229E, RSV, rhinovirus, metapneumovirus, influenza,
adenovirus, bocavirus, and enterovirus. Chest x-ray and brain
CT scans did not reveal abnormalities; the CSF analysis for
cells, glucose, and protein was normal. PCRs for herpes virus
family (HSV-1, HSV-2, and VZV) and enterovirus in CSF
were negative. Bacteria cultures in blood, urine, and CSF were
also negative.
During hospitalization, three interictal
electroencephalograms (EEG) and a cerebral 1.5T MRI
showed normal results. Levetiracetam was started the 1st day
as prophylactic antiepileptic treatment (28 mg/Kg/day), but
the infant presented with another afebrile seizure on April 4,
consisting of upright tonic eye deviation, clonic movements
of face muscles, and tonic posture of four limbs in extension,
lasting 90 s. The seizure was recorded by the mother and was
checked by pediatric neurologists. Pre-dosing blood levels
of levetiracetam were within therapeutic range (15 mcg/mL;
normal values 10–40). Hydroxychloroquine was then started
on April 4, as compassionate use due to the persistence of
seizures in a COVID-19 setting, at a dosage of 6.5 mg/Kg/day
for 5 days with excellent tolerance. Blood test controls revealed
a sustained decrease of ferritin values, with a late increase
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of D-dimer levels. Unfortunately, D-dimer control was not
possible due to technical procedures. The rest of the lab tests
were within normal limits. Following discharge, the patient
was followed as an outpatient, and she presented with normal
neurological development and an absence of seizures. A timeline
of clinical course, lab test, and investigations is summarized
in Figure 1. Informed and written consent to publish clinical
details was obtained from the parents. Additionally, during
hospitalization, the patient and her mother were included
in a collaborative study of genomic medicine for identifying
genetic variants causing hyperimmunity due to SARS-CoV-2
infection. The local ethics committee approved the study.
Whole exome sequencing was performed, and prioritized
genes were analyzed. No pathogenic variants of susceptibility
genes for hyperimmunity were found, but both the infant
and the mother carried a loss-of-function variant in the
PRRT2 gene (NM_145239.3), c.649dupC (p.Arg217fs), at the
heterozygous state. This frameshift variant has been recurrently
described in ClinVar as pathogenic. It is associated with benign
familial infantile convulsions (OMIM 605751), but it is also
allelic to infantile convulsions and choreoathetosis (OMIM
602066) (19). A revision of maternal family history revealed
that the mother could have had two convulsions during late
infancy, related to mild infections and fever, with normal
development afterwards.
DISCUSSION
SARS-CoV-2 infection in children is being increasingly
recognized. However, detailed clinical data are still lacking and
individual cases, such as the one presented, can shed some light
to comprehend the complex systemic manifestations of this
disease in the youngest.
A review of the Chinese Center for Disease Control and
Prevention on February 24 has shown than <1% of the COVID-
19 cases were in children younger than 10 years of age (20). In
Wuhan Children’s Hospital, China, 1,391 children were tested
through February, and a total of 171 (12.3%) were positive
for SARS-CoV-2 infection, with a median age of 6.7 years. Of
these, 65% presented pneumonia and three required invasive
mechanical ventilation. Only 18% of the positive children were
infants younger than 1 year of age, and no cases were reported
with neurological features. In Spain, by March 16, 41 of the
4,695 confirmed cases (0.8%) in the Madrid region were children
younger than 18 years, and 60% of the pediatric cases required
hospitalization (21). In a systematic review of SARS-CoV-2
infection in children, Castagnoli et al. found, by April 22, 444
participants younger than 10 years of age, but no details about
clinical symptoms were revealed (22).
Our infant presented with afebrile seizures during the course
of COVID-19, some of themwith focal semiology, and these were
FIGURE 1 | Timeline course of the patient’s COVID-19 disease.
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not associated with signs of encephalitis, structural damage, or
other concomitant infection. The clinical picture is compatible
with the definition of non-febrile illness seizures, which occur in
association with an acute infection the week before or 3 days after
the seizure, although without presenting with fever on the day of
the seizure (3, 23).
Besides respiratory symptoms, HCoV infections may present
with febrile seizures in susceptible infants (9–12). Very recently,
a febrile convulsion in a 2-years-old girl with COVID-19 was
reported (15). However, several studies have suggested that non-
febrile illness seizures are a different seizure category from febrile
seizures or unprovoked seizures. Non-febrile illness seizures may
share some genetic predisposition in a similar manner as febrile
seizures or epilepsy, and, as with febrile seizures, the prognosis is
favorable in most cases (3).
This pandemic has sparked an interest in genomic medicine
to elucidate host determinants of phenotype severity (24, 25).
We thus performed whole exome sequencing as described
(26) and uncovered the genetic predisposition of the infant
to develop afebrile seizures due to a well-known recurrent
pathogenic PRRT2 mutation associated with benign familial
infantile convulsions (OMIM 605751) and infantile convulsions
and choreoathetosis (OMIM 602066) (19). In the mother,
the phenotype is benign and self-limited, without movement
disorders. Nonetheless, a long-term follow-up is required to
detect the possible development of dyskinesias in the infant.
Regarding other investigations in this case, ferritin levels were
increased at admission, on day 6 since symptoms onset, and
they progressively decreased over time. D-dimers were within
normal limits at admission but increased during hospitalization.
These findings resemble the hyperimmune response found is
adult COVID-19 severe cases, a major driver of adverse outcome
(27, 28). Same findings are being reported in severe COVID-19
in children (8), and, during the SARS-CoV epidemic of 2002,
some patients presented with decreased lymphocyte count and
increased levels of LDH and D-dimers.
Therapeutic strategies and evidence-based protocols for
COVID-19 treatment in children are still lacking. On April 4, we
thus decided to treat our infant with hydroxychloroquine since
this drug is renowned for its antiviral and immunomodulating
properties (29), and it has been previously used in young
infants (30–33). Preliminary results of hydroxychloroquine
on adults COVID-19 clinical trials suggested that 600mg
daily may decrease viral load in nasal swabs (34), but
further studies has raised concerns about its use during
hospitalization (35). On July 4, the WHO International Steering
Committee discontinued clinical trials for hydroxychloroquine in
hospitalized patients (www.who.int/news-room).
One limitation of this case is related to the storing of the
biological samples. PCR of SARS-CoV-2 in CSF was not available
at that moment, and the sample was not stored. Moreover,
hyperimmune response in younger children is an uncommon
phenomenon and warrants further research in samples of the
patients. We would like to encourage pediatricians to collect and
store biological samples of patients with COVID-19 for further
analysis, as it would be useful for future research.
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